Background Convalescent plasma (CP) transfusion is an early option for treating infections
with pandemic potential, often preceding vaccine or antiviral drug rollout. Heterogenous …

Human clinical studies investigating use of convalescent plasma (CP) for treatment of
coronavirus disease 2019 (COVID-19) have produced conflicting results. Outcomes in these …

Early in the SARS-CoV-2 pandemic, there was a high level of optimism based on
observational studies and small controlled trials that treating hospitalized patients with …

Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is
uncertain for the treatment of novel coronavirus disease 2019 (COVID‐19). Our goal is to …

Currently, there are no approved specific antiviral agents for 2019 novel coronavirus
disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test …

Background Convalescent plasma (CP) has been widely used to treat COVID-19 and is
under study. However, the variability in the current clinical trials has averted its wide use in …

Convalescent plasma, collected from donors who have recovered from a pathogen of
interest, has been used to treat infectious diseases, particularly in times of outbreak, when …

Convalescent plasma (CP) has been used to treat emerging infectious diseases for over a
century. It was notably deployed during the 1918 flu pandemic and has been explored …

The utility of COVID-19 convalescent plasma (CCP) for treatment of immunocompromised
patients who are not able to mount a protective antibody response against SARS-CoV-2 and …

BACKGROUND: The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing
infection in exposed, uninfected individuals is unknown. We hypothesized that CCP might …